From "helpful tool" to "essential platform": the perception shift that doubles deal size
Design
Jul 8, 2026
You won the evaluation. The reorder came through. And then it plateaued. The customer likes your product, reaches for it now and then, and files you under “useful, when we remember.” You are a line item, not a dependency.
Most teams already know they would rather be the platform a workflow is built around than a tool in the drawer. The harder question is how you get there. The answer is not more features. It is repositioning.
Being a necessity beats being a nice-to-have
This part is quick, because most people already agree with it.
A nice-to-have gets transactional reorders, constant price pressure, and an easy exit the moment something cheaper shows up. A necessity gets expansion inside the account and retention that compounds. Across B2B software, the companies that compound are the ones that grow within existing accounts, with top-quartile net revenue retention running north of 120% to 130% (ChartMogul). Everyone wants to be on that side of the line. So let us skip the sales pitch and get to the part teams actually get wrong.
You cannot become a platform on tool-era positioning
Here is the trap. Teams try to become a platform by adding capabilities while keeping the same positioning that sold the tool. It does not work, because the category a buyer files you under is set by how you position, not by how many features you ship.
Positioning is not fixed. It is supposed to mature as a company hits new inflection points. The story that won your first customers, a sharp tool that does one job well, is the wrong story for the next stage, the layer a workflow depends on. If your positioning still says “we do X really well” while you hope to be treated as infrastructure, the buyer hears “useful tool” and prices you accordingly. That gap, between how you are positioned and how you want to be valued, is exactly where growth stalls.
The market makes the point for us. Platforms carry a durable premium over single-product peers, the “platform premium” visible across the Bessemer Cloud Index. In life science, 2025 capital concentrated on “differentiated platforms that address well-defined biological or technical bottlenecks”. The premium is paid for the category, and the category is a positioning decision, not a feature list.
So does the shift “double deal size”? Not by magic, and not for everyone. But it moves the levers that set deal size: which category you compete in, how you expand inside an account, and how hard you are to replace. Those move together, and they move when the position changes, not when the feature count does.
The inflection point is not “add more.” It is “reposition deliberately, then let the product and the proof catch up to the new position.”
How to reposition as a platform
Repositioning is a sequence of proof, not a tagline swap. For a reagents and tools company, four moves do the work.
1. Reframe around the workflow, not the feature. Stop describing the job your product does and start describing the part of the customer’s process that now runs on you. The unit of value shifts from “a task” to “a workflow,” and so does the price.
2. Prove reproducibility in public. A platform is something others build on, which means it has to be trusted to behave the same way every time. Application notes and customer case studies that show repeatable results are what turn “interesting” into “we can standardize on this.”
3. Make the expansion path visible. Show portfolio range, not a point solution. If buying you once clearly implies buying you again, the buyer starts evaluating you as infrastructure rather than a one-off purchase.
4. Earn the language of the field. Move from “this works” to “this is what teams in our space standardize on.” Platform status is partly conferred by the market, so you earn it by being described that way by others, not only by yourself.
Notice that none of these is a feature request. Each is a way of proving you belong at the center of the workflow, which is what the new position claims.
What this looks like in practice
When we worked with Atlas Biotech, the temptation was to describe what the technology did: run deep mutational scans. Instead we repositioned the capability as the thing a customer’s de-risking depends on, the map you generate before committing a program. Same science, moved from a service you buy to a decision you build on.
Repositioning is a milestone, not a rebrand
The story that sold the tool will not sell the platform, and bolting the word “platform” onto the old positioning fools no one. Positioning has to mature with the company, deliberately, at each inflection point. That is strategic marketing tied to a moment, not a logo refresh. It also depends on the discipline in our piece on generic messaging, and it has to show up in the website and materials that carry the story.
Want to know which category your buyers currently put you in, and what it is costing you in expansion? Apply for Signal for an external read.